BeiHai Kangcheng-B (01228): CAN103 for the treatment of Gaucher's Disease (GD) qualifies for priority review.

Beihai Kangcheng-B (01228) announced CAN103 (Vilapine β) for the treatment of Gaucher's disease (GD)...

Zhitong FinanceSep 30 08:15 ET

Express News | CANbridge Pharmaceuticals Inc - Grant of Priority Review Status of Can103 for Treatment of Gaucher Disease

ReutersSep 30 08:14 ET

Beihai Kangcheng-B (01228.HK) appoints Fangxin Li as a non-executive director.

Grondragon September 30th |Beihai Kangcheng-B(01228.HK) announced that Fangxin Li has been appointed as a non-executive director and a member of the board of directors' remuneration committee, effective from September 30, 2024. The board of directors has also received the resignation letter of Hu Zhengguo as a non-executive director and a member of the board of directors' remuneration committee, effective from the date of effectiveness.

Gelonghui FinanceSep 30 05:41 ET

Express News | CANbridge Pharmaceuticals Inc - James Qun Xue Will Assume Interim Duties and Responsibilities of CFO

ReutersSep 30 05:37 ET

Express News | CANbridge Pharmaceuticals Inc - Glenn Hassan Has Tendered His Resignation as Chief Financial Officer

ReutersSep 30 05:36 ET

CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease has been granted Priority Review Status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

CANbridgeSep 30 00:49 ET